The history of the Flu Vaccine from 1940 to 2030

In 1918, about 50 million people, or one-fifth of the world’s population, became infected with the virus known as the “Spanish” flu, according to the Centers for Disease Control and Prevention (CDC).

“The 1918 Pandemic was the reason the military was so invested in getting a vaccine during World War II. They had seen what happened during World War I,” said Catherine Troisi, Ph.D., infectious disease epidemiologist and an associate professor at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.

Developing an influenza vaccine took more than a decade. Clinical trials began in the 1930s and researchers worked closely with U.S. military officials during World War II. In 1945, the first flu vaccine was approved for military use in the U.S. The following year, the vaccine was approved for civilians.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO shortlisted in European Mediscience Awards 2023

    The European Mediscience Awards is now in its 21st year, having been held every year since inception in 2002. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing

    hVIVO plc

    Cocrystal receives approval from HREC for Phase I trial

    Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19. CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology. The double-blind, randomised, dose-escalating, placebo-controlled study aims to to

    hVIVO plc

    hVIVO’s Dr Andrew Catchpole on conducting challenge trials

    Introducing Dr Catchpole As Chief Scientific Officer, Dr Catchpole has “overall responsibility for the scientific conduct” of hVIVO’s studies and laboratory services, and oversees the manufacturing of their challenge viruses. He runs the team that designs the studies

    hVIVO plc

    The people who get paid to get sick

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Case study: Non-clinical consultancy

    IntroductionA small sized pharmaceutical company, who had already performed proof-of-concept studies with a small molecule drug candidate came to Venn Life Sciences with the aim to bring their product into clinic as soon as possible. ChallengesThe company’s first

    hVIVO plc

    Advancing of novel antimalarial drug and vaccine candidates

    The Challenge Malaria is a serious and life-threatening, mosquito borne disease prevalent across much of tropical and sub-tropical Asia, South America and Sub-Saharan Africa. Due to increasing resistance to current antimalarial regimens, new drugs are required as both

    hVIVO plc

    hVIVO Annual Report and Accounts now available

    hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for

    hVIVO plc

    hVIVO transformative year with revenue up 30% to £50.7m

    hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its audited results for the 12 months

    hVIVO plc

    What is RSV – Understanding the Virus

    Everybody knows what the common cold and influenza are, but we’d guess not many have heard of RSV (Respiratory Syncytial Virus). So, what it is? Well, it is a very common virus that leads to mild, cold like

    hVIVO plc

    hVIVO at World Vaccine Congress Washington 2023

    Chief Scientific Officer, Andrew Catchpole discusses hVIVO’s attendance at the World Vaccine Congress in Washington. hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory

    hVIVO plc

    hVIVO to publish results on 25 April 2023

    hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its audited final

    hVIVO plc

    Advantages to centralising laboratory services at hVIVO

    Clinical field studies are a critical part of the drug development and approval process. They are conducted to evaluate the safety, immunogenicity, and efficacy of a new drug. These studies require careful monitoring, attention to detail, significant logistics,

    hVIVO plc

    Positive results from hVIVO study of Cidara flu candidate

    hVIVO – a company focused on testing global infectious and respiratory disease products through clinical trials – has recorded positive interim results from its study involving Cidara Therapeutics’ CD388 influenza therapy. hVIVO is currently conducting the wider phase

    No more posts to show